|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
10
|
|
pubmed:dateCreated |
2006-10-20
|
|
pubmed:abstractText |
In 27 patients randomized to receive commercial trivalent influenza vaccine (TIV) containing 15 microg of the hemagglutinin (HA) of influenza A (H3N2 and H1N1) and B virus or a recombinant vaccine (rHAO) containing 15, 45, or 135 microg of each HA, reactogenicity was minor. Among patients with similar prevaccination titers, 40% given 45 microg and 60% given 135 microg of rHAO developed an increase in influenza A/H3 neutralizing antibody levels; there were no increases in 4 given TIV. For each vaccine, the highest frequencies of increases in neutralizing antibody levels and the highest mean titers occurred in those given the 135- microg vaccine.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0022-1899
|
|
pubmed:author |
pubmed-author:BodeyGerald PGP,
pubmed-author:CouchRobert BRB,
pubmed-author:FayadLuis ELE,
pubmed-author:GoyAndre HAH,
pubmed-author:HagemeisterFredrick BFB,
pubmed-author:KwakLarry WLW,
pubmed-author:McLaughlinPeterP,
pubmed-author:ProBarbaraB,
pubmed-author:RaadIssam III,
pubmed-author:RodriguezGilhen HGH,
pubmed-author:RodriguezM AlmaMA,
pubmed-author:RomagueraJorge EJE,
pubmed-author:SafdarAmarA,
pubmed-author:WangMichaelM
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
194
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1394-7
|
|
pubmed:dateRevised |
2007-12-3
|
|
pubmed:meshHeading |
pubmed-meshheading:17054068-Antibodies, Viral,
pubmed-meshheading:17054068-Baculoviridae,
pubmed-meshheading:17054068-Dose-Response Relationship, Immunologic,
pubmed-meshheading:17054068-Double-Blind Method,
pubmed-meshheading:17054068-Female,
pubmed-meshheading:17054068-Hemagglutinins, Viral,
pubmed-meshheading:17054068-Humans,
pubmed-meshheading:17054068-Influenza A Virus, H1N1 Subtype,
pubmed-meshheading:17054068-Influenza A Virus, H3N2 Subtype,
pubmed-meshheading:17054068-Influenza B virus,
pubmed-meshheading:17054068-Influenza Vaccines,
pubmed-meshheading:17054068-Lymphoma, B-Cell,
pubmed-meshheading:17054068-Male,
pubmed-meshheading:17054068-Middle Aged,
pubmed-meshheading:17054068-Neutralization Tests,
pubmed-meshheading:17054068-Vaccines, Synthetic,
pubmed-meshheading:17054068-Viral Proteins
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Dose-related safety and immunogenicity of baculovirus-expressed trivalent influenza vaccine: a double-blind, controlled trial in adult patients with non-Hodgkin B cell lymphoma.
|
|
pubmed:affiliation |
Department of Infectious Diseases, Infection Control, and Employee Health, University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA. asafdar@mdanderson.org
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, N.I.H., Extramural
|
